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BACKGROUND: Systemic lupus erythematosus (SLE) patients living in Indonesia are prone to tuberculosis (TB) infection, since this country 
ranks second globally for TB prevalence. Isoniazid, an 
anti-tuberculosis (TB) drug, is metabolized by enzyme 
N-acetyltransferase 2 (NAT2) that is encoded by NAT2 
gene. NAT2 haplotype, referring as acetylator status, 
may predispose as genetic factor in SLE development or 
complicate SLE therapy. This study explored the NAT2 
haplotypes and acetylator status among SLE patients living 
in a TB endemic area. 
METHODS: Genomic  DNA  of  260  registered  SLE 
patients at The Rheumatology Clinic of Dr. Hasan Sadikin 
General  Hospital,  Bandung,  Indonesia  were  isolated. 
NAT2 gene was amplified and sequenced, then NAT2 
haplotypes and the acetylator status among SLE patients 
with  or  without  TB  history  were  determined  and 
presented.
RESULTS: Most of SLE patients registered were female 
(n=250; 96.2%). The median age of patients when SLE was 
diagnosed for the first time was 27 years old (8-69 years), 
with organ involvement predominantly in musculoskeletal 
(80.8%) and mucocutaneous (73.1%). TB history, mostly 
pulmonary TB, was present in 23.1% of SLE patients 
of whom TB was diagnosed before SLE (10.4%) or after 
SLE (10.7%) or both before and after SLE (2%). The 
acetylator status was mostly intermediate (61.5%) with the 
NAT2*4/*6B was the most prevalent haplotype (25.8%).
CONCLUSION: There is a high number of intermediate 
and low acetylator status among SLE patients. Since these 
SLE patients live in TB endemic area, the NAT2 acetylator 
status determination among SLE patients before starting 
TB therapy may have clinical benefit to decrease a possible 
drug induced liver injury, and this warrants further study. 
KEywORDS: NAT2, acetylator, systemic lupus 
erythematosus, tuberculosis
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Introduction
Systemic lupus erythematosus (SLE) is a complex chronic 
condition due to abnormality of immune system. The 
etiology of SLE is still unknown, as the SLE immune 
system has lost their self-tolerance resulting in an immune 
dysregulation.(1) Recently, genetic involvement in SLE 
is becoming central, triggered by environmental i.e., UV 
exposure, smoking and other stochastic factors such as 
hormonal factor, some infections and many other factors 
contributing to the development of disease.(2) Genome 
wide association studies have shown evidence and propose 
some candidate regions towards susceptibility to SLE from 
variation in many genes, especially in the host immune 
system. Certain genes involved in the pathway of toll like 
receptors (TLR) and type 1 interferon, immune signal 
transduction, immune complex processing may play roles 
in the SLE susceptibility.(3) Interestingly, genes i.e., signal 
transducer and activator of transcription 4 (STAT4), protein 
tyrosine phosphatase non-receptor type 22 (PTPN22), 
Tumor necrosis factor, alpha-induced protein 3 (TNFAIP3), 
and many other genes that are expressed in SLE, these genes 
are also expressed in other autoimmune diseases, such as 
rheumatoid arthritis.(3)
 Furthermore, various drugs may also induce SLE 
known as drug induced SLE (DILE), among others 
isoniazid (INH), a tuberculosis (TB) antibiotic, that is 
metabolized by N-acetyltransferase2 (NAT2) enzyme.
(4) This catalytic enzyme, encoded by NAT2 gene, has a 
pivotal role in detoxifies and inactivates some drugs for 
example hydrazine drugs, as well as xenobiotics,  and also 
metabolizes carcinogenic arylamines and other chemicals in 
the liver.(5) Interestingly, INH, as one of the primary TB 
drugs, has been used as a model drug in silico to determine 
acetylation phenotype.(6) 
 The acetylation phenotype or acetylation rate varies 
from person to person.(7) Individual acetylation rate or 
acetylator status is classified into rapid, intermediate or slow 
acetylators, based on the co-dominant expression of NAT2 
haplotypes.(8) NAT2 gene, located at chromosome 8p22, 
exhibits several variants, comprising NAT2 haplotype. 
The haplotype heterozygous NAT2*4/*6 and homozygous 
NAT2*5/*5 has been reported to be more frequent in 
SLE patients, compared to control group of which the 
NAT2*5/*6 is more prevalent.(9) Interestingly, the slow 
acetylator individual may be prone to develop SLE later in 
life.(10)
 Since the NAT2 haplotype varies among population, 
the aim of this study was to determine the distribution 
of NAT2 acetylator status which was explored among 
SLE patients with or without TB history from Bandung, 
Indonesia, as this country is a TB endemic area.(11) 
Methods
Design of The Study
The design of this study was a descriptive cross-sectional 
study, exploring the NAT2 acetylator status among SLE 
patients living in a TB endemic area, therefore, history of 
TB in SLE patients was assessed.
Recruitment of SLE Patients 
This study was part of a larger SLE patient registry at The 
Rheumatology Clinic of Dr. Hasan Sadikin General Hospital 
(Dr. Hasan Sadikin Lupus Regitry, (HSLR)). Consecutive 
clinical data of SLE patients registered during January 
2016 to May 2018 were collected, including TB history 
and treatment. SLE patients were further grouped into 
SLE patients with or without history of TB. No exclusion 
criteria in this study. Systemic Lupus Erythematosus 
Disease Activity Index (SLEDAI) index and organ damage 
were assessed.(12) The study protocol was approved by 
the  Ethical  Research  Committee  of  Medical  Faculty, 
Universitas Padjadjaran No. 36/UN6.KEP/EC/2018. 
DNA Extraction and Amplification
During a routine visit in the outpatients clinic, blood 
samples were collected into ethylenediaminetetraacetic 
acid (EDTA)-coated tubes. DNA was extracted and stored 
at -20oC according to the manufacturer's instructions 
(Qiagen, Hilden, Germany). NAT2 gene was amplified 
in a final volume of 50 µL, containing of 1U polymerase 
chain reaction (PCR) MyTaq™ HS Master Mix (Bioline, 
London, UK), 20μM for each primer forward and reverse 
as published earlier (13), and 200ng DNA template. PCR 
was performed by PCR Thermal Cycler Eppendorf 5331 
Mastercycler (Marshall Scientific, Hampton, USA) with 
PCR condition as followed: 95oC initiation phase for 3 
min, followed by 35 cycles of denaturation at 95oC for 15 
s, annealing at 50oC for 15 s, and elongation at 72oC for 60 
s, and ended by a cycle of final extension at 72oC for 5 min. 
The PCR product was further sequenced for one direction of 
forward sequencing. NAT2 gene variants were then aligned 
and acetylator status was determined.  
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Molecular Analysis of NAT2 Variants and Acetylator 
Status Determination
Sequence of NAT2 gene was analyzed using ClustalX for 
multiple alignments with sequence reference from GenBank 
(Acc. No. KR231610). Variants of NAT2 gene were assessed 
and the acetylator status of SLE patients was determined and 
classified into three groups, including slow, intermediate 
and fast acetylator based on NAT2 acetylator nomenclature 
(http://nat.mbg.duth.gr/Human%20NAT2%20alleles_2013.
htm.). In brief, fast acetylation is coded by wild-type 
NAT2*4 alleles or NAT2*13, while impaired acetylation 
has various alleles i.e. intermediate (heterozygous) or slow 
(homozygous) acetylator status was determined according 
to nucleotide change in 341 T>C (NAT2*5), 590 G>A 
(NAT2*6), 857 G>A (NAT2*7). When sequences were 
found not in nomenclature yet, they were designated as ‘ND 
(cannot determined)’. 
During January 2016 to May 2018, 264 consecutive SLE 
patients, older than 16 years old were registered at The 
Rheumatology Outpatient Clinic of Dr. Hasan Sadikin 
General Hospital, Bandung, Indonesia. Only 260 DNA of 
these SLE patients were successfully sequenced for NAT2 
haplotype and acetylator status was then determined. At 
Results
Male
(n=10)
Female
(n=250) p- value
Median (min-max) 34.5 (16-47) 32 (16-73) 0.873
<50 years 10 (3.8) 230 (88.4) n.d
>50 years - 20 (7.6)
Median (min-max) 30.5 (13-42) 27 (8-69) 0.824
<15 years 1 (0.4) 10 (3.8) n.d
15-50 years 9 (3.5) 232 (89.2)
>50 years - 8 (3.1)
Non-smoker 4 (40) 198 (79.2) n.d
Active smoker 3 (30) 3 (1.2)
Passive smoker 3 (30) 49 (19.2)
Age at SLE diagnosis; years
Age Group at SLE diagnosis; n (%)
Smoking; n (%)
Characteristics
Age; years
Age Group; n (%)
Table 1.  Clinical characteristics of SLE patients registered at Dr. Hasan Sadikin 
General Hospital, Bandung, Indonesia, during January 2016 to May 2018.
SLE: systemic lupus erythromatosus; n.d not determined.
the time of inclusion in the study, only 245 (94.2%) SLE 
patients were still followed up, 9 were lost and 6 died due 
to infection, particularly caused by community acquired 
pneumonia. 
 SLE patients registered were predominantly female 
(96.2%; n=250) of whom 6% (n=20) were female >50 
years old. The median age when SLE was diagnosed was 
27 years old (range 8-69 years), and no statistical different 
(p=0.824) between male and female patients as shown in 
Table 1. Interestingly, 4.2% (n=11) of these SLE patients 
were diagnosed at young age of <15 years old, and 3.1% 
(n=8) were at older age of >50 years old. Most of the female 
SLE patients were non-smokers (76.1%; n=198 of 250) in 
contrast to male SLE patients who were active or passive 
smokers (60%, n=6 of 10). Of note, passive smokers were 
present in 49 of 250 (19.6%) female SLE patients (Table 1). 
As for clinical involvement, the most affected organs were 
musculoskeletal (80.8%) and mucocutaneous (73.1%) as 
depicted in Table 2. Disease activity of lupus at the time of 
subjects recruited was measured with SLEDAI showed that 
most patients (71.6%) had no disease activity. Up to 98.9% 
patients received methylprednisolone, while the other given 
drugs is described in Table 2. 
 Patients were grouped into SLE patients with no TB 
history (n=200; 76.9%), SLE patients with TB history, 
consisting TB history before SLE diagnosis (n=27; 10.4%), 
after SLE diagnosis (n=28; 10.7%) and in both periods of 
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Table 2. Organ involvement, disease activity, SLE 
therapy and TB history during SLE period. among 
patients from Dr. Hasan Sadikin General Hospital, 
Bandung, Indonesia.
*SLEDAI: Systemic Lupus Erythematosus Disease 
Activity Index.
n (%)
210 (80.8)
190 (73.1)
118 (45.4)
86 (33.1)
45 (17.3)
189 (71.6)
66 (25)
8 (3)
1 (0.4)
261 (98.9)
143 (54.2)
147 (55.7)
48 (18.2)
10 (3.8)
16 (6.1)
14 (5.3)
200 (76.9)
60 (23.1)
Pulmonary TB 15 (5.8)
Extra Pulmonary 12 (4.6)
Pulmonary TB 17 (6.5)
Extra Pulmonary 11 (4.2)
5 (2)
TB history
TB pre SLE
TB post SLE
TB pre & post SLE
Chloroquine
Cyclophosphamide
Methotrexate
Cyclosporine
Mycophenolate mofetil
No TB history
No Activity
Mild
Moderate
Severe
Methylprednisolone
Azathioprine
Categories
Organ Involvement
SLEDAI*
SLE Therapy 
TB history 
Musculoskeletal
Mucocutanous
Nephritis
Hematological
Neuropsychiatric
before and after SLE diagnosis (n=5; 2.0%) as shown in 
Table 2 with detailed pulmonary or extra pulmonary TB. All 
patients with TB history were asked for their TB treatment, 
and INH was noted as one of the drugs among TB regiment 
of all these patients.
NAT2 Haplotype and Acetylator Status Among SLE 
Patients
The sequences of NAT2 gene variants were analysed in this 
study. The most prevalent variant was G590A (55.4.%), 
consisting of heterozyogous GA (45%) and homozygous 
AA (10.4%) as this variant was dominant in NAT2*6 
haplotype, while others were C282T (30.4%), T341C 
(16.9%), C481T (10.8%), A803G (16.9%), G857A (21.5%) 
(shown in Supplement 1). Analysis of the haplotype wild 
type NAT2*4 (21.5%), haplotype NAT2*6B (25.8%) and 
NAT2*6A (12.7%) were the most prevalent haplotype in 
SLE patients from Bandung, Indonesia as shown in Table 
3. The acetylator status among SLE patients from Bandung 
were detected in trimodale mode as fast acetylator (59 cases; 
22.7%) consisted of NAT2*4 wild type and NAT2*12A 
(homozygous or heterozygous), and as intermediate (160 
cases; 61.5%) and slow acetylator (37 cases; 14.3%). We 
have found new variants in NAT2 gene in our samples (n4; 
1.5%) that did not belong to known haplotype. 
NAT2 Acetylator Status and TB History Among SLE 
Patients
There were 32 patients who had TB history before SLE was 
diagnosed of whom 27 had TB only before SLE diagnosis 
and 5 others had TB in both periods i.e., before and after 
SLE diagnosis as shown in Table 4. Most of the SLE patients 
recovered well from TB infection. 
Discussion
The immunopathogenesis of SLE is complex and not fully 
understood yet.(14) Gene interaction to some drugs and/
or enzymes that metabolize certain drugs may play an 
important role. This is the first SLE study in Indonesia, 
exploring NAT2 haplotypes and acetylator status among 
SLE patients recruited from SLE registry in TB endemic 
area Bandung, Indonesia. 
 The distribution of NAT2 variants and haplotypes 
have been extensively studied in different ethnic groups. 
The most prevalent variant in our study is G590A (55.4%), 
while study in Brazil is G857A.(15) The distribution of 
the most prevalent NAT2 haplotypes in our study are the 
wild type NAT2*4 (21.5%), haplotype NAT2*6B (25.8%) 
and NAT2*6A (12.7%) (Table 3); and the acetylator status 
among SLE patients from Bandung fast acetylator (22.7%), 
intermediate (61.5%) and slow (14.3%). Slow acetylator 
may have impacted the TB therapy with the development 
of drug induced liver injury (DILI) or hepatotoxicity, as 
confirmed by several studies across population.(16-18) 
Therefore, individual with slow acetylator status may have 
been exposed with TB drugs longer, especially INH, and 
prone to develop SLE.(19)
 Study in Japan showed that environmental factor such 
as cigarette smoking has been associated with increased risk 
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Rapid Intermediate (heterozygous) Slow Unknown††
56 - - - 56 21.5
3 - - - 3 1.2
NAT2*5A - 1 - - 1 0.4
NAT2*5B - 11 3 - 14 5.4
NAT2*5C - 2 - - 2 0.8
NAT2*5D - 4 1 - 5 1.9
NAT2*5E - 2 - - 2 0.8
NAT2*5KA† - 1 - - 1 0.4
NAT2*5Q† - 1 - - 1 0.4
NAT2*5S† - 1 - - 1 0.4
NAT2*5T† - 2 - - 2 0.8
NAT2*5TA† - 2 - - 2 0.8
NAT2*5U† - 11 - - 11 4.2
NAT2*6A - 6 27 - 33 12.7
NAT2*6B - 67 - - 67 25.8
NAT2*6F† - 4 - - 4 1.5
NAT2*6J† - 23 - - 23 8.8
NAT2*7A - 17 - - 17 6.5
NAT2*7B - 1 6 - 7 2.7
NAT2*7C† - 2 - - 2 0.8
- 2 - 4 6 2.3
59 160 37 4 260
22.7 61.5 14.3 1.5 100
Total (n)
%
Total
(n) %
NAT2*4 (wild type)
NAT2*12A
NAT2*5
NAT2*6
NAT2*7
ND†
NAT2  Acetylator Status
Table 3. Haplotype distribution among NAT2 acetylator status of SLE patients registered at Dr. Hasan Sadikin 
General Hospital, Bandung, Indonesia
NAT2 haplotype according to http://nat.mbg.duth.gr/Human%20NAT2%20alleles_2013.htm. ND (cannot determined): 
haplotype not in nomenclature yet; †: haplotype with unknown acetylator status, however, intermediate and slow 
acetylator status is determined according to nucleotide change in 341 T>C (NAT2*5), 590 G>A (NAT2*6), 857 G>A 
(NAT2*7); ††: unknown acetylator status.
to SLE, especially in individual with NAT2 slow acetylator 
genotype.(9) Tobacco, the ingredients of cigarette, is 
classified into aromatic amines that needs to be detoxified by 
N-acetyltransferase enzyme. Passive smoker are prevalent 
among female SLE patients (19.2%) where the household 
members especially male are smokers. 
 Furthermore, study results of NAT2 acetylator status 
in relation with SLE are conflicting. Eventhough slow 
acetylators are more prevalent in SLE patients compared 
to their healthy controls, 9 others studies showed lack of 
evidence for this asscociation.(20,21) In our study, we are 
lacking of control group, therefore, the real association of 
slow acetylator status and susceptibility to SLE could not be 
further analyzed. 
 Although the result is contradicting, we have drawn 
special attention on TB history among SLE patients 
as Indonesia harbors TB patients being the second of 
TB prevalence globally, and thus the chance of getting 
Mycobacterium tuberculosis infection is high and latent 
TB infection may exist. Infection is known as one of 
the common trigger factors for SLE. Study showed that 
Mycobacterium tuberculosis infection may have a role in 
precipitating  SLE  through  immunomodulatory  action.
(22,23) In the other hand, SLE patient is vulnerable to 
180
Print ISSN: 2085-3297, Online ISSN: 2355-9179The Indonesian Biomedical Journal, Vol.11, No.2, August 2019, p.175-81
Rapid Intermediate Slow Unknown††
N N (%) N (%) N (%) N (%)
200 43 (21.5) 129 (64.5) 29 (14.5) 4 (2.0)
before SLE diagnosis 27 8 (29.6) 15 (55.6) 4 (14.8) -
after SLE diagnosis 28 6 (21.4) 18   (64.3) 4 (14.3) -
before & after SLE diagnosis 5 2 (40.0) 3 (60.0) - -
32
Recovered 26 7 (21.9) 15 (46.9) 4 (12.5)
Relapse 5 2 (15.6) 3 (9.4) -
Failed 1 1 (3.1) - -
33
Recovered 26 6 (18.2) 16 (48.5) 4 (12.1)
Relapse 5 2 (6.1) 3 (9.1) -
Failed 1 - 1 (3.0) -
Died 1 - 1 (3.0) -
after SLE diagnosis**
Total
NAT2  Aceytolator Status
TB prevalence 
TB therapy outcome
SLE with no TB history
SLE with TB history
before SLE diagnosis*
Table 4. NAT2 acetylator status distribution in association with TB prevalence and TB therapy outcome among 
SLE patients with history of TB registered at Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.
SLE: Systematic Lupus erythematosus; TB: tuberculosis; n.d: not determined. * SLE patients with TB before SLE 
and with TB before & after SLE diagnosis together. ** SLE patients with TB after SLE and with TB before & after 
SLE diagnosis together. ††: unknown acetylator status, however, intermediate and slow acetylator status is determined 
according to nucleotide change in 341 T>C (NAT2*5), 590 G>A (NAT2*6), 857 G>A (NAT2*7).
infection due to dysregulation of multiple aspects in the 
immune system.(24) Interestingly, some antibiotics against 
infections in particular may also predispose the SLE 
development, known as DILE.(19) 
 Mycobacterium tuberculosis infection may develop 
after SLE. This infection is possible due to various 
immunosuppressive or corticosteroid agent needed for 
SLE therapy, either infection from the neighboring people 
or latent TB infection re-activation. An extra pulmonal 
tuberculosis infection is common (25) although in our 
study extra pulmonal TB has an equal percentage compared 
to pulmonary TB. When TB infection after SLE is 
diagnosed, the NAT2 acetylator status determination may 
have beneficial of clinical importance, not only for SLE 
chemotherapy but also for TB therapy. Further studies on 
pharmacokinetic, -dynamics and –genetic in SLE drugs may 
have a great interest.(26) 
The Limitation of The Study
This NAT2 acetylator status study does not compare 
SLE patients as cases vs. healthy individuals as controls, 
therefore, this study is limited and can not explore the 
analysis regarding the role of NAT2 acetylator status and 
SLE susceptibility. As for TB history, no laboratory data 
on liver function, thus, drug induced liver injury can not 
be assessed.  An integrative SLE and TB collaborative care 
need to be implemented.
Conclusion
The distribution of intermediate and slow NAT2 acetylator 
status among SLE patients from Bandung, Indonesia is 
predominant as high as 65.4% and 11.9%, respectively. 
In the area where TB prevalence is high, acetylator status 
determination among SLE patients may have an important 
role before INH therapy to guide for successful TB treatment. 
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